Importer of Controlled Substances Application: Adiramedica, LLC, 31344-31345 [2021-12290]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
31344
Federal Register / Vol. 86, No. 111 / Friday, June 11, 2021 / Notices
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: The
Commission has received a complaint
and a submission pursuant to § 210.8(b)
of the Commission’s Rules of Practice
and Procedure filed on behalf of Crocs,
Inc. on June 8, 2021. The complaint
alleges violations of section 337 of the
Tariff Act of 1930 (19 U.S.C. 1337) in
the importation into the United States,
the sale for importation, and the sale
within the United States after
importation of certain casual footwear
and packaging thereof. The complainant
names as respondents: Cape Robbin Inc.
of Pomona, CA; Bijora, Inc., d/b/a Akira
of Chicago, Il; Carol Wright Enterprise
LLC of Bloomfield, NJ; Dr. Leonard’s
Healthcare Corp. of Edison, NJ; Crocsky
of Austin, TX; Fullbeauty Brands Inc. d/
b/a Kingsize of New York, NY; Hawkins
Footwear, Sports, Military & Dixie Store
of Brunswick, GA; Hobibear Shoes and
Clothing Ltd. of Brighton, CO; Hobby
Lobby Stores, Inc. of Oklahoma City,
OK; Ink Tee of Los Angeles, CA; La
Modish Boutique of West Covina, CA;
Legend Footwear, Inc., d/b/a Wild Diva
of City of Industry, CA; Loeffler Randall
Inc. of New York, NY; Maxhouse Rise
Ltd. of Hong Kong; New Genesis Online
LLC of Newcastle, WA; PW Shoes, Inc.
a/k/a P&W of Maspeth, NY; SG
Footwear Meser Grp. Inc. a/k/a S.
Goldberg & Co. of Hackensack, NJ; ShoeNami, Inc. of Gretna, LA; Sketchers
USA, Inc. of Manhattan Beach, CA; Star
Bay Group Inc. of Hackensack, NJ; Yoki
Fashion International LLC of New York,
NY; Quanzhou ZhengDe Network Corp.,
d/b/a Amoji of China; 718Closeouts of
Brooklyn, NY; Royal Deluxe
Accessories, LLC of New Providence,
NJ; and Fujian Huayuan Well Import
and Export Trade Co., Ltd. of China. The
complainant requests that the
Commission issue a general exclusion
order, or in the alternative a limited
exclusion order, and cease and desist
orders.
Proposed respondents, other
interested parties, and members of the
public are invited to file comments on
any public interest issues raised by the
complaint or § 210.8(b) filing.
Comments should address whether
issuance of the relief specifically
requested by the complainant in this
investigation would affect the public
health and welfare in the United States,
competitive conditions in the United
States economy, the production of like
or directly competitive articles in the
United States, or United States
consumers.
In particular, the Commission is
interested in comments that:
VerDate Sep<11>2014
19:14 Jun 10, 2021
Jkt 253001
(i) Explain how the articles
potentially subject to the requested
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the requested remedial
orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or third
party suppliers have the capacity to
replace the volume of articles
potentially subject to the requested
exclusion order and/or a cease and
desist order within a commercially
reasonable time; and
(v) explain how the requested
remedial orders would impact United
States consumers.
Written submissions on the public
interest must be filed no later than by
close of business, eight calendar days
after the date of publication of this
notice in the Federal Register. There
will be further opportunities for
comment on the public interest after the
issuance of any final initial
determination in this investigation. Any
written submissions on other issues
must also be filed by no later than the
close of business, eight calendar days
after publication of this notice in the
Federal Register. Complainant may file
replies to any written submissions no
later than three calendar days after the
date on which any initial submissions
were due. No other submissions will be
accepted, unless requested by the
Commission. Any submissions and
replies filed in response to this Notice
are limited to five (5) pages in length,
inclusive of attachments.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above. Submissions should refer
to the docket number (‘‘Docket No.
3551’’) in a prominent place on the
cover page and/or the first page. (See
Handbook for Electronic Filing
Procedures, Electronic Filing
Procedures 1). Please note the
Secretary’s Office will accept only
electronic filings during this time.
Filings must be made through the
Commission’s Electronic Document
Information System (EDIS, https://
edis.usitc.gov.) No in-person paperbased filings or paper copies of any
1 Handbook
for Electronic Filing Procedures:
https://www.usitc.gov/documents/handbook_on_
filing_procedures.pdf.
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
electronic filings will be accepted until
further notice. Persons with questions
regarding filing should contact the
Secretary at EDIS3Help@usitc.gov.
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
By order of the Commission.
Issued: June 8, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–12310 Filed 6–10–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–848]
Importer of Controlled Substances
Application: Adiramedica, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
2 All contract personnel will sign appropriate
nondisclosure agreements.
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
E:\FR\FM\11JNN1.SGM
11JNN1
Federal Register / Vol. 86, No. 111 / Friday, June 11, 2021 / Notices
Adiramedica, LLC. has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 12, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 12, 2021.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021,
Adiramedica, LLC., 585 Turner
Industrial Way, Aston, Pennsylvania
19014, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
jbell on DSKJLSW7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Schedule
Tapentadol ........................
9780
II
The company plans to import
Tapentadol (9780) in dosage form for
clinical trials. No other activity for this
drug code is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12290 Filed 6–10–21; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
19:14 Jun 10, 2021
Jkt 253001
NATIONAL ARCHIVES AND RECORDS
ADMINISTRATION
[NARA–2021–026]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
National Archives and Records
Administration (NARA).
ACTION: Notice of proposed extension
request.
AGENCY:
We are proposing to request
an extension from the Office of
Management and Budget (OMB) of a
currently approved information
collection, ‘‘Use of NARA Official Seals
and Logos.’’ Members of the public and
other Federal agencies provide
information under this collection as part
of their requests to use our official
seal(s) and logo(s). We invite you to
comment on this proposed information
collection pursuant to the Paperwork
Reduction Act of 1995.
DATES: We must receive written
comments on or before August 10, 2021.
ADDRESSES: Send comments by email to
tamee.fechhelm@nara.gov. Because our
buildings are temporarily closed during
the COVID–19 restrictions, we are not
able to receive comments by mail during
this time.
FOR FURTHER INFORMATION CONTACT:
Tamee Fechhelm, Paperwork Reduction
Act Officer, by email at
tamee.fechhelm@nara.gov or by
telephone at 301.837.1694 with requests
for additional information or copies of
the proposed information collection and
supporting statement.
SUPPLEMENTARY INFORMATION: Pursuant
to the Paperwork Reduction Act of 1995
(Pub. L. 104–13), we invite the public
and other Federal agencies to comment
on proposed information collections. If
you have comments or suggestions, they
should address one or more of the
following points: (a) Whether the
proposed information collection is
necessary for NARA to properly perform
its functions; (b) our estimate of the
burden of the proposed information
collection and its accuracy; (c) ways we
could enhance the quality, utility, and
clarity of the information we collect; (d)
ways we could minimize the burden on
respondents of collecting the
information, including through
information technology; and (e) whether
this collection affects small businesses.
We will summarize any comments
you submit and include the summary in
our request for OMB approval. All
comments will become a matter of
public record.
SUMMARY:
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
31345
In this notice, we solicit comments
concerning the following information
collection:
Title: Use of NARA Official Seals and
Logos.
OMB number: 3095–0052.
Agency form number: N/A.
Type of review: Regular.
Affected public: Business or other forprofit, not-for-profit institutions, Federal
Government.
Estimated number of respondents: 37.
Estimated time per response: 15
minutes.
Frequency of response: On occasion.
Estimated total annual burden hours:
9 hours.
Abstract: The authority for this
information collection is contained in
36 CFR 1200.8. NARA’s three official
seals are the National Archives and
Records Administration seal; the
National Archives seal; and the
Nationals Archives Trust Fund Board
seal. The official seals are used to
authenticate various copies of official
records in our custody and for other
official NARA business. We also have
an official NARA logo, and other official
program and office logos (such as the
Federal Register logo, Presidential
library logos, Controlled Unclassified
Information logo, National Historical
Publications and Records Center logo,
and more). Occasionally, when criteria
are met, we will permit the public or
other Federal agencies to use our official
seals and logos. The requestor must
submit a written request, that includes
certain information outlined in 36 CFR
1200, to use the official seals and logos.
We approve or deny the request using
specific criteria, also outlined in the
regulation.
Swarnali Haldar,
Executive for Information Services/CIO.
[FR Doc. 2021–12268 Filed 6–10–21; 8:45 am]
BILLING CODE 7515–01–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
National Endowment for the Arts
National Council on the Arts 203rd
Meeting
National Endowment for the
Arts, National Foundation on the Arts
and the Humanities.
ACTION: Notice of meeting.
AGENCY:
Pursuant to section 10(a)(2) of
the Federal Advisory Committee Act, as
amended, notice is hereby given that a
meeting of the National Council on the
Arts will be held open to the public by
videoconference or teleconference.
SUMMARY:
E:\FR\FM\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 86, Number 111 (Friday, June 11, 2021)]
[Notices]
[Pages 31344-31345]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12290]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-848]
Importer of Controlled Substances Application: Adiramedica, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
[[Page 31345]]
SUMMARY: Adiramedica, LLC. has applied to be registered as an importer
of basic class(es) of controlled substance(s). Refer to Supplementary
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 12, 2021.
Such persons may also file a written request for a hearing on the
application on or before July 12, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021, Adiramedica, LLC., 585 Turner
Industrial Way, Aston, Pennsylvania 19014, applied to be registered as
an importer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Tapentadol..................................... 9780 II
------------------------------------------------------------------------
The company plans to import Tapentadol (9780) in dosage form for
clinical trials. No other activity for this drug code is authorized for
this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-12290 Filed 6-10-21; 8:45 am]
BILLING CODE P
